Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 35, Issue 3, 2012, Pages 317-321

  Kurdoglu, Z ^a   Ozkol, H ^a   Tuluce, Y ^a   Koyuncu, I ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

Author keywords

Antioxidant status; Insulin resistance; Oxidative stress; PCOS

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CARBONYL DERIVATIVE; CATALASE; GLUCOSE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GONADOTROPIN; INSULIN; MALONALDEHYDE; PRASTERONE SULFATE; RETINOL; TESTOSTERONE;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; OXIDATION;

ADULT; ANTIOXIDANTS; BETA CAROTENE; BLOOD GLUCOSE; BODY WEIGHT; CATALASE; FEMALE; GLUCOSE TOLERANCE TEST; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HOMEOSTASIS; HORMONES; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MALONDIALDEHYDE; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; PROTEIN CARBONYLATION; VITAMINS; YOUNG ADULT;

EID: 84862842750     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7682     Document Type: Article

References (46)

1. Ji LL, Gomez-Cabrera MC, Vina J. Role of free radicals and antioxidant signaling in skeletal muscle health and pathology. Infect Disord Drug Targets 2009, 9: 428-44.
2. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001, 34: 407-13.
3. Betteridge DJ. What is oxidative stress? Metabolism 2000, 49 (Suppl 1): 3-8.
4. Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 2009, 47: 372-81.
5. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003, 80: 123-7.
6. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 2003, 80: 252-4.
7. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38: 1165-74.
8. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983, 57: 356-9.
9. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab 2007, 18: 273-9.
10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81: 19-25.
11. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22: 141-6.
12. Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010, 26: 281-96.
13. Uzel N, Sivas A, Uysal M, Oz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. Horm Metab Res 1987, 19: 89-90.
14. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991, 11: 81-128.
15. Telci A, Cakatay U, Kayali R, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res 2000, 32: 40-3.
16. Bouayed J, Bohn T. Exogenous antioxidants - Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev 2010, 3: 228-37.
17. Behrman HR, Preston SL, Aten RF, Rinaudo P, Zreik TG. Hormone induction of ascorbic acid transport in immature granulosa cells. Endocrinology 1996, 137: 4316-21.
18. Murray AA, Molinek MD, Baker SJ, et al. Role of ascorbic acid in promoting follicle integrity and survival in intact mouse ovarian follicles in vitro. Reproduction 2001, 121: 89-96.
19. Hanukoglu I. Antioxidant protective mechanisms against reactive oxygen species (ROS) generated by mitochondrial P450 systems in steroidogenic cells. Drug Metab Rev 2006, 38: 171-96.
20. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19: 41-7.
21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15: 539-53.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
23. Aebi H. Catalase. In: Bergmeyer H (ed). Methods of enzymatic analysis. New York: Academic Press. 1974, 673-7.
24. Mannervik B, Guthenberg C. Glutathione transferase (human placenta). Methods Enzymol 1981, 77: 231-5.
25. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999, 13: 23-30.
26. Suzuki J, Katoh N. A simple and cheap methods for measuring serum vitamin A in cattle using only a spectrophotometer. Nippon Juigaku Zasshi 1990, 52: 1281-3.
27. Omaye ST, Turnbull JD, Sauberlich HE. Ascorbic acid analysis II. Determination after derivatisation with 2.2. dinitrophenylhydrazine. Selected methods for determination of ascorbic acid in animal cells, tissues and fluids. In: McCorn DB, Wright L (eds). Methods Enzymology. New York: Academic Press. 1979, 7-8.
28. Martinek RG. Method for the determination of vitamin E (total tocopherols) in serum. Clin Chem 1964, 10: 1078-86.
29. Hegde KR, Henein MG, Varma SD. Establishment of mouse as an animal model for study of diabetic cataracts: biochemical studies. Diabetes Obes Metab 2003, 5: 113-9.
30. Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186: 464-78.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193: 265-75.
32. Kuscu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009, 88: 612-7.
33. Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009, 204: 509-14.
34. Palacio JR, Iborra A, Ulcova-Gallova Z, Badia R, Martinez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol 2006, 144: 217-22.
35. Kaya C, Erkan AF, Cengiz SD, Dunder I, Demirel OE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and non-traditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril 2009, 92: 1372-7.
36. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006, 21: 104-8.
37. Karadeniz M, Erdogan M, Tamsel S, et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes 2008, 116: 231-5.
38. S. Kandasamy, R. Inmozhi Sivagamasundari, A. Bupathy, S. Sethubathy, V. Gobal. Evaluation of insulin resistance and oxidative stress in obese patients with polycystic ovary syndrome. Int J Appl Biol Pharmacol Technol 2010, 1: 391-8.
39. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008, 65: 233-9.
40. Rodrigues JK, Dib LA, Ferriani RA, Jordao Junior AA, Navarro PA. Serum markers of oxidative stress and assisted reproduction procedures results in infertile patients with polycystic ovary syndrome and controls. Rev Bras Ginecol Obstet, 32: 118-25.
41. Zhang D, Luo WY, Liao H, Wang CF, Sun Y. The effects of oxidative stress to PCOS. Sichuan Da Xue Xue Bao Yi Xue Ban 2008, 39: 421-3.
42. Olusi SO. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotective enzymes in humans. Int J Obes Relat Metab Disord 2002, 26: 1159-64.
43. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23: 434-9.
44. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114: 1752-61.
45. Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod 2008, 23: 1602-6.
46. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91: 336-40.